Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Krystal Biotech is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 119 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $84.22 |
|---|---|
| 52-week range | $47.67 - $85.65 |
| 50-day moving average | $77.56 |
| 200-day moving average | $70.33 |
| Wall St. target price | $107.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.48 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $84.22 from 2023-01-27
| 1 week (2023-01-24) | 1.18% |
|---|---|
| 1 month (2022-12-30) | 6.31% |
| 3 months (2022-10-31) | 10.09% |
| 6 months (2022-07-29) | 16.04% |
| 1 year (2022-01-28) | 56.66% |
|---|---|
| 2 years (2021-01-29) | 20.83% |
| 3 years (2020-01-31) | 61.16% |
| 5 years (2018-01-30) | 738.84% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -13.4% |
| Return on equity TTM | -27.34% |
| Profit margin | 0% |
| Book value | $21.03 |
| Market capitalisation | $2.2 billion |
TTM: trailing 12 months
We're not expecting Krystal Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $47.67 up to $85.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 0.8762. This would suggest that Krystal Biotech's shares are less volatile than average (for this exchange).
Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.